The National Healthcare Security Administration (NHSA) supports high-level innovative drugs in securing reasonable returns during their initial market launch phase and has instituted a price stabilization period. Concurrently, the NHSA has streamlined the online listing process, implementing a collaborative review and handling model where "one province accepts and processes applications, with all regions applying the same standards," to expedite the clinical utilization of these novel medications.